Lung Density

Analysis™

FDA CLEARED, CE Mark Certified

FUNCTIONAL ASSESSMENT FOR COPD

COPD affects more than 60M people globally and is the 4th leading leading cause of death worldwide.1 It is widely accepted that COPD presents as a mixture of parenchymal tissue destruction (emphysema) and small airways disease (obstructive bronchitis), and that the ability to distinguish between these relative components is a significant need for improving patient assessment and enabling personalized treatment.



THE POWER OF PERSONALIZED, QUANTITATIVE IMAGING

Lung Density Analysis ™ applies big data analysis to paired inspiratory / expiratory chest CT studies to provide visualization and quantification of lung regions with abnormal tissue density. Functional LDA is the only fully-automated, regulatory cleared image analysis providing a complete mapping of normal lung, air-trapping and areas of persistent low density (< -950 HU, which may be indicative of emphysema2) in a combined image to help visualize the components of COPD. LDA provides a full 3D DICOM series with density overlays for detailed interpretation and a quantitative report of density categories by lung region, enabling data-based decisions for personalized care.









Fully Automated Efficiency

Imbio is unique in delivering full quantitative analysis and 3D visualization without added work for radiology. LDA is fully automated and inserts results directly into the patient study in your PACS in just minutes.


BREAKTHROUGHS BY PHYSICIANS FOR PHYSICIANS

logo Imbio works with the most trusted names in healthcare to bring breakthrough image analysis to daily clinical care. Functional Lung Density Analysis™ is based on the patented PRM (Parametric Response Mapping) technology pioneered at the University of Michigan.

While recognized as today’s standard of diagnosis, pulmonary function tests (PFT’s) alone can be inconclusive. As many as 1/3 of individuals with respiratory symptoms may have normal PFT’s.3 Imbio LDATM utilizing PRM provides visualization and quantification of the components of COPD not available through PFT’s, supporting more personalized diagnosis, therapy tracking and surgical or interventional procedure planning.



References
1. World Health Organization. Accessed online Feb 1, 2017. http://www.who.int/respiratory/copd/en/
2. Wang et al. Optimal threshold in CT quantification of emphysema. Eur Radiol. 2013 Apr;23(4):975-84.
3. Regan E, et al. Clinical and Radiologic Disease in Smokers with Normal Spirometry. JAMA Intern Med. 2015. Doi:10.1001/jamainternmed.2015.2735.